Eledon Pharmaceuticals, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David-Alexandre C. Gros
- Full Time Employees
- 33
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 19900 MacArthur Boulevard Irvine CA United States of America 92612
- IPO Date
- Sep 17, 2014
- CIK
- 0001404281
- Website
- eledon.com
- Similar Companies
- Business
- Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company specializing in the development of therapies to prevent rejection of transplanted organs and to treat autoimmune diseases. The company’s primary product candidate is tegoprubart, an anti-CD40L antibody designed to regulate immune system activity that leads to organ rejection. Eledon's product pipeline focuses on transplantation immunology, including applications in kidney transplantation and xenotransplantation, with research ongoing into its potential benefits for transplant recipients and patients with autoimmune conditions such as amyotrophic lateral sclerosis. Founded in 2015 and headquartered in Waltham, Massachusetts, Eledon operates primarily in the United States with ongoing global clinical trials. Eledon’s core offerings include immunosuppressive biologics under development, particularly tegoprubart, which targets the CD40 Ligand pathway crucial for immune regulation in transplanted organs. The company is advancing tegoprubart through late-stage clinical trials, including the Phase 2 BESTOW trial in kidney transplant recipients, which showed favorable safety and efficacy outcomes comparable to current standards of care with improved profiles on adverse effects. Eledon also explores the compound’s use in islet transplantation for type 1 diabetes and has reported promising initial patient results in this area. Recent major developments include completion of enrollment for the BESTOW Phase 2 trial several months ahead of schedule, with topline results expected in late 2025. Eledon reported positive interim data from this trial, demonstrating non-inferiority to tacrolimus with benefits in kidney function and reduced incidence of new-onset diabetes and other complications. The company successfully raised approximately $50 million in a November 2025 public offering to fund ongoing operations through late 2026. Eledon also shared encouraging early data from a trial involving tegoprubart in immunosuppressive regimens post islet transplantation in type 1 diabetes, indicating potential expanded therapeutic applications. Eledon targets the biotechnology and pharmaceutical industry segments focused on organ transplantation and autoimmune disorders. Its strategic progression includes advancing its lead asset through pivotal trials with the goal of regulatory approval for kidney transplantation to mitigate organ rejection and improve transplant outcomes globally. The company continues to build on its immunology expertise and clinical development pipeline with the aim of becoming a leader in transplant immunosuppressive therapies. In summary, Eledon Pharmaceuticals manufactures and develops immunosuppressive therapies centered on its lead biologic tegoprubart for transplant rejection prevention and potential autoimmune disorder treatment, advancing through critical clinical stages and backed by recent funding and promising trial results. The company emphasizes improving transplant recipient outcomes through novel mechanisms targeting immune system pathways.
Company News
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
647,812 Shares in Eledon Pharmaceuticals, Inc. $ELDN Acquired by ADAR1 Capital Management LLC
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Eledon: At The Center Of The Next Medical Frontier
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation Transcript
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives $9.67 Average Target Price from Brokerages